NCT06884982

An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib

An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with Iparomlimab and Tuvonralimab Injection Combined with Lenvatinib

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Northern Jiangsu People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-center, single-arm, prospective trial to explore the efficacy and safety of neoadjuvant treatment with Iparomlimab and Tuvonralimab Injection combined with lenvatinib in patients with advanced HCC

Conditions

• HCC - Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	QL1706 Plus Lenvatinib	All enrolled subjects will receive QL1706 5 mg/kg intravenously plus lenvatinib 8/12mg on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).

Timeline

• Start date: 2025-03-13
• Primary completion: 2027-09-30
• Completion: 2028-09-30
• First posted: 2025-03-19
• Last updated: 2025-03-19